You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Hierarchical, Layout-Aware, Radiation Effects Tools Vertically Integrated into an EDA Design Flow for Rad-Hard by Design

    SBC: Reliable MicroSystems, LLC            Topic: DTRA16A003

    The goal of this workis to establish a radiation-aware capability in a commercial EDA design flow that will enable first-pass success in radiation resiliency for DoD ASIC designs in much the same way that existing EDA design suites ensure first pass functionality and performance success of complex ASICs destined for commercial applications.Such an integrated capability does not presently exist.The ...

    STTR Phase II 2018 Department of DefenseDefense Threat Reduction Agency
  3. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE, LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Aminoglycosides with reduced ototoxicity via miRNA targeting

    SBC: NUBAD, LLC            Topic: NIAID

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low cost methods to develop aminoglycosides with anti- ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced o ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke

    SBC: Translational Sciences Inc.            Topic: NHLBI

    Seventeen million people each year suffer from an ischemic stroke and millions are left dead and disabledTreatment with recombinant tissue plasminogen activatorr tPAis only modestly effective at reducing disability and it is associated with brain hemorrhage in up toof patients when serial imaging studies are performedBrain hemorrhage causes death and disability andis the major cause of early morta ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil

    SBC: AcePre, LLC            Topic: NCCIH

    PROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Identifying hereditary cancer patients in low-resource community cancer settings using an innovative informatics solution

    SBC: SGgenomics, Inc.            Topic: 101

    PROJECT SUMMARYHereditary cancer risk assessment in low resource community cancer settings is a signi cant unmet clinical needUnfortunatelymost community cancer clinics do not have adequate access to genetics expertise and patients are not systematically assessed for hereditary riskNew cost e ective and practical approaches are needed to assess and identify patients at risk for hereditary cancer c ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Fully Human Antibodies for the Prevention of Respiratory Syncytial Virus

    SBC: IDBiologics, Inc.            Topic: NIAID

    The goal of this STTR is to provide a preclinically validated monoclonal antibody or antibody combination for the prevention of respiratory syncytial virusRSVin high risk patients including infants and the elderlyWorldwideof children are infected with RSV before the age ofresulting in an estimatedmillion lower respiratory tract infectionsIn the United States adults overhavemillion RSV infections c ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Novel Clinical Diagnostic Assay for Peripheral T-cell Lymphoma (PTCL)

    SBC: HEALTHCHART LLC            Topic: 102

    Project Summary Abstract Peripheral T cell lymphomaPTCLis a heterogeneous cancer that constitutes up toof all non Hodgkin lymphomaNHLThe World Health Organization classification recognizes a number of distinct subtypes of PTCL but the diagnosis of these different subtypes is challenging even for expert hematopathologistsFurthermoreof PTCL cases are not classifiable into any specific subtype at all ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government